临床试验/NCT07296315

NCT07296315招募中2 期

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Confirm Efficacy and Safety of MH002 and to Assess the Effect of Dose in Patients With Mild-to- Moderate Ulcerative Colitis Insufficiently Controlled With 5-Aminosalicylic Acid

MRM Health NV26 个研究点分布在 4 个国家目标入组 204 人开始时间: 2026年4月3日最近更新: 2026年9月9日

干预措施

试验速览

阶段: 2 期
状态: 招募中
发起方: MRM Health NV
入组人数: 204
试验地点: 26
主要终点: Change from baseline in centrally-assessed Mayo Endoscopic Subscore (MES) at Week 12

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验相关资讯

研究概览

简要总结

The main goal of the study is to check if MH002 works and is safe to use. In a previous study in 45 patients with Ulcerative Colitis, MH002 was found to have favorable effects. In this study, 2 different doses will be tested, and long-term treatment effects will be investigated.

MH002 is a live biotherapeutic product (LBP). This is a biological medicine containing live bacteria used to restore the normal function of a gut that is damaged by ulcerative colitis (UC). Ulcerative colitis is a bowel disease that causes inflammation and sores in the gut.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围: 16 Years 至 —（Child, Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Documented diagnosis (histologic diagnosis and either endoscopic or radiographic diagnosis) of ulcerative colitis (UC) at least 3 months prior to Screening.
•Diagnosis of active mild-to-moderate UC at Screening as defined by an mMS of 4 to 7, including a MES ≥2 (confirmed by central reading), a Mayo Rectal Bleeding score of 1 or 2, and a Mayo Stool Frequency score ≥
•UC lesions extending ≥10 cm from the anal verge.
•Participant must either receive a stable dose of orally administered 5-aminosalicylic acid (5-ASA); have failed, due to insufficient efficacy, oral 5-ASA; have a documented intolerance or poor tolerance to an aminosalicylic acid treatment, including 5-ASA, or be contra-indicated to receive 5-ASA treatment per local labeling.
•Participant must provide written informed consent or assent (parent or legal guardian must provide consent for a participant <18 years of age who has assented to participate in the study, or as required per local regulations).
•In countries not allowing females of childbearing potential (FOCBP) to participate without an acceptable contraceptive method, the FOCBP must agree to abide to local requirements and eg, use at least an acceptable method of contraception until the end of treatment.

排除标准

•Diagnosis of Crohn's disease, undetermined colitis, ischemic colitis, fulminant colitis, or toxic megacolon.
•Evidence of a clinically significant, active infection of the gastrointestinal tract.
•Severe UC (mMS>7), meeting modified Truelove Witts' criteria and/or RB score of 3, participant with ulcerative proctitis only, or participant in whom colitis is most severe in the transverse colon or ascending colon, or if any hospitalization is planned at the time of Screening.
•Total colectomy, stoma, or ileo-anal pouch, or history of extensive colonic resection leaving less than 30 cm of colon.
•Presence of intra-abdominal fistula, abscesses, diverticulitis, or gastrointestinal bleeding unrelated to UC.
•History of colon carcinoma or high-grade dysplasia.
•Previous use of any advanced UC treatment, including any anti-TNF (eg, infliximab), antiintegrin (eg, vedolizumab) or anti-IL-12/23 (eg, ustekinumab) agent, anti-IL23 (eg, risankizumab), Janus kinase inhibitors (eg, tofacitinib), and sphingosine-1-phosphate receptor modulators (eg, etrasimod).
•Use of sulfasalazine ≤4 weeks prior to randomization.
•Use of corticosteroids or any disease-modifying antirheumatic drugs (DMARD), including thiopurines, ≤6 weeks prior to randomization into the study, except for a stable, low dose of oral corticosteroids (≤10 mg prednisolone/day) for at least 2 weeks prior to Screening colonoscopy and up to at least the Week 12 visit.
•Use of antibiotics (except for local use), prebiotics, or probiotics ≤4 weeks prior to randomization or anticipated during study participation, or concomitant, chronic use of an antidiarrheal drug, or concomitant use of any rectal treatment.
•Use of fecal microbiota transplantation (FMT) ≤52 weeks prior to randomization.
•Treatment with another investigational drug or intervention within 30 days prior to Screening, or within 5 times the elimination half-life of the investigational drug (whichever is longest).
•Any immunocompromised state, including conditions linked to severe immunosuppression (eg, active human immunodeficiency virus, malignancies, liver cirrhosis, systemic chemotherapy).
•Leukopenia (total white blood cell count <3000/μL) and/or neutropenia (absolute neutrophil count <1000/μL), anemia (hemoglobin <10.0 g/dL), thrombocytopenia (peripheral blood platelet count <100 × 10^9/L), and/or any coagulation disorder with significantly increased risk of bleeding.
•Ongoing or recent (<3 months) renal disease or insufficiency as manifested, eg, by medical history and/or clinical examination and/or (calculated or measured) glomerular filtration rate ≤60 mL/min.
•Ongoing or recent (<3 months) advanced hepatic dysfunction defined as a Child Pugh score ≥10 (Class C), or increase ≥2 times the upper limit of normal in aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (TB), prothrombin time (PT) or international normalised ratio (INR).
•Clinically significant bone marrow disease if progressive or not controlled, or any history of solid organ or bone marrow transplantation.
•Active intravenous drug abuse or alcohol abuse disorder as assessed by the Investigator.
•Pregnancy or lactation at study entry. Note: Participants who become pregnant or start to breastfeed during the study may continue the study per the Investigator's discretion.
•Participants who are inappropriate for the study per the Investigator's discretion.
•An employee (or a relative of) of the Investigator, study center, contract research organization, or Sponsor.

研究组 & 干预措施

Placebo

Placebo Comparator

干预措施: Placebo (Drug)

Low-dose MH002

Experimental

干预措施: Low-dose MH002 (Drug)

High-dose MH002

Experimental

干预措施: High-dose MH002 (Drug)

结局指标

主要结局

Change from baseline in centrally-assessed Mayo Endoscopic Subscore (MES) at Week 12

时间窗: Week 12

次要结局

To confirm the efficacy of MH002 to induce clinical remission at Week 12(Week 12)
(Median) Percent change from baseline in fecal calprotectin (FC) at Week 12(Week 12)
Change from baseline in histologic scores Robarts' Histopathology Index (RHI) at Week 12(Week 12)
Change from baseline in UC-100 score at Week 12(Week 12)
Change from baseline in PRO-2 score at Week 12(Week 12)
To confirm the safety and tolerability of MH002 in the Induction Phase(Up to Week 12)

研究者

发起方

MRM Health NV

申办方类型

Industry

责任方

Sponsor

研究点 (26)

Loading locations...

相似试验

尚未招募

3 期

MHB018A Treatment in Patients With Chronic Thyroid Eye Disease

NCT07257185Minghui Pharmaceutical (Hangzhou) Ltd150

招募中

2 期

Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)Ulcerative Colitis

NCT07265570InSilico Medicine Hong Kong Limited80

招募中

2 期

A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)Focal Segmental Glomerulosclerosis

NCT07268638Akebia Therapeutics60

招募中

2 期

Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis

NCT07284459Contineum Therapeutics324

进行中（未招募）

2 期

Taldefgrobep Alfa in Adults With Overweight and ObesityObesity

NCT07281495Biohaven Therapeutics Ltd.150